The man behind Keytruda is back to ring the bell.
Eikon Therapeutics, led by former Merck research chief Roger Perlmutter, has set terms for its Nasdaq debut (“EIKN”). The company is targeting a valuation of $908 million, seeking to raise up to $317.7 million as the biotech IPO window creaks open in early 2026.
🔬 THE PEDIGREE PLAY: Investors are buying into a rare combination of executive legend and scientific royalty:
- The CEO: Perlmutter is credited with shepherding Keytruda into the world’s best-selling drug. Eikon’s lead asset, EIK1001, is currently in mid-to-late stage trials in combination with Keytruda for skin cancer.
- The Science: Co-founded by Nobel Prize winner Eric Betzig, Eikon utilizes super-resolution microscopy to track protein movement in living cells—a high-throughput platform designed to uncover targets invisible to traditional methods.
📊 THE OFFERING:
- Range: $16 – $18 per share.
- Shares: 17.65 million.
- Backers: Having raised over $1 billion privately, the cap table includes heavyweights like Lux Capital, Foresite Capital, and The Column Group.
🌤️ MARKET THAW: Eikon joins a growing queue of 2026 listings (including SpyGlass Pharma and Aktis Oncology), signaling that the “Biotech Winter” of 2025 may finally be thawing.
💡 ANALYST TAKEAWAY: This is the ultimate “Jockey” bet. While the platform technology is groundbreaking, the valuation is heavily anchored to Perlmutter’s track record of execution. With trial data expected in H2 2026, public investors are effectively paying an IPO premium to see if the man who defined modern immuno-oncology can do it again with a microscope instead of a molecule.
👇 Biotech Investors: Do you value the “Platform Potential” of Nobel-winning tech, or is the valuation purely driven by the “Perlmutter Premium”?